ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is providing an update on the use of its “at-the market” equity offering program.
As earlier disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to implement a “at the market” equity offering system under which Acasti might issue and market from time to time its everyday shares having an aggregate offering price of up to seventy five dolars million throughout the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions reported on January twenty seven, 2021, Acasti granted an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 million. The ATM Shares were offered at prevailing market costs averaging US$1.0747 per share. No securities had been marketed through the facilities of the TSXV or, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July 7, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with the services of theirs. As a consequence of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and outstanding as of March 5, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and often will supply the Company with supplemental freedom in its ongoing review process to enjoy as well as evaluate strategic options.
About Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically concentrated on the research, commercialization and development of prescription drugs using OM3 greasy acids delivered both as totally free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have substantial clinical proof of safety and efficacy in lowering triglycerides in patients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being developed for clients with serious HTG.
Forward Looking Statements – ACST Stock
Statements in that press release that are not statements of current or historical truth constitute “forward looking information” to the meaning of Canadian securities laws and “forward-looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking statements include known and unknown risks, uncertainties, along with other unknown variables that may result in the particular results of Acasti to be materially different from historical results and from any later results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks as well as uncertainties, people are urged to give some thought to statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other similar expressions to be forward-looking and uncertain. People are actually cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this particular press release. Forward-looking assertions in that press release include, but are not confined to, info or statements about Acasti’s strategy, succeeding operations and its review of strategic alternatives.
The forward-looking assertions found in this specific press release are expressly qualified in their entirety by this alerting statement, the “Special Note Regarding Forward Looking Statements” section found in Acasti’s newest annual report on Form 10 K and quarterly report on Form 10 Q, which are actually readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and also on the investor section of Acasti’s website at www.acastipharma.com. All forward-looking statements in that press release are made as of the day of this press release.
ACST Stock – Acasti does not undertake to redesign any such forward-looking statements whether as a consequence of info that is brand new , future events or otherwise, except as needed by law. The forward looking assertions contained herein are also subject generally to risks and assumptions and uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities and The Canadian and exchange Commission securities commissions, like Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage